R. Ziemiecki

First name
R.
Last name
Ziemiecki
Johannes, C. B., Beachler, D. C., Layton, J. B., Danysh, H. E., Ziemiecki, R., Arana, A., et al. (2022). Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01263-3
View
Danysh, H. E., Johannes, C. B., Beachler, D. C., Layton, J. B., Ziemiecki, R., Arana, A., et al. (2022). Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01262-4
View
Arana, A., Margulis, A. V., McQuay, L. J., Ziemiecki, R., Bartsch, J. L., Rothman, K. J., et al. (2018). Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study. Pharmacotherapy. http://doi.org/10.1002/phar.2121
View
Fortuny, J., Gilsenan, A., Cainzos-Achirica, M., Cantero, O. F., Flynn, R. W. V., Garcia-Rodriguez, L., et al. (2019). Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350. Drug Saf. http://doi.org/10.1007/s40264-019-00836-z
View
Gilsenan, A., Fortuny, J., Cainzos-Achirica, M., Cantero, O. F., Flynn, R. W. V., Garcia-Rodriguez, L., et al. (2019). Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-019-00835-0
View
Ruigomez, A., Plana, E., Gilsenan, A., Fortuny, J., Cainzos-Achirica, M., Flynn, R. W. V., et al. (2021). Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride. Drug Saf. http://doi.org/10.1007/s40264-021-01044-4
View